SecBot SecBot
SECBOTREPLAY Home › Report › PALI

PALI · Soleus Capital 8.6% stake

PALISADE BIO, INC. · SC 13G/A filed Nov 9, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 9, 2026 at 16:30 ET

Soleus Capital Master Fund, L.P. filed an amended Schedule 13G disclosing a 8.6% passive stake in Palisade Bio, Inc., holding 14,996,154 shares as of September 30, 2026. This is an increase from the prior filing by Vanguard (5.16%) and from Soleus's own prior filing (not provided in detail), indicating continued accumulation by a hedge fund manager. The filing remains passive (Rule 13d-1(c)), with no activist intent signaled.

  • Soleus Capital Master Fund, L.P. holds 14,996,154 shares of Palisade Bio common stock, representing 8.6% of shares outstanding as of September 30, 2026.
  • The percentage is based on 174,270,558 shares outstanding as of August 6, 2026 (per the issuer's Form 10-Q).
  • The filing is an amendment to Schedule 13G, indicating a passive investment under Rule 13d-1(c).
  • Soleus Capital, LLC is the general partner; Soleus Capital Group, LLC is the managing member; Soleus Capital Management, L.P. is the investment manager; Guy Levy is the sole managing member of the relevant entities.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access